ABQ TransfemNM Support Group

Hits: 40

International Androgen Blockers in Gender-Affirming Care for Transgender Women

Generated by https://chat.greenpt.ai on 6 Sep 2026

The Main Options Worldwide

Gender-affirming hormone therapy for transgender women typically combines estrogen with an antiandrogen to suppress testosterone. The principal androgen blockers used internationally are:

  1. Spironolactone — A potassium-sparing diuretic with antiandrogenic properties. It is the most commonly prescribed antiandrogen in the United States, typically at doses of 100 to 200 mg/day (up to 400 mg/day). It is FDA-approved for other conditions (heart failure, hypertension) but used off-label for testosterone suppression. Spironolactone is also used in other countries, though less commonly as a first-line agent where alternatives are available.
  2. Cyproterone acetate (CPA) — Marketed as Androcur, CPA is a steroidal antiandrogen and progestin that directly suppresses testosterone production and blocks androgen receptors. It is widely used in Europe, Canada, and most of the rest of the world, typically at doses of 50 to 100 mg/day. CPA is not approved by the FDA and is unavailable in the United States, which is the primary reason it is not prescribed there.
  3. GnRH agonists (e.g., leuprorelin, goserelin, triptorelin) — These are considered the gold standard for testosterone suppression globally because they act at the level of the pituitary to shut down gonadal hormone production entirely. However, their use is significantly limited by high cost, which restricts access in many healthcare systems.
  4. Bicalutamide — A nonsteroidal antiandrogen that blocks androgen receptors without suppressing testosterone production directly. It is gaining interest as an alternative because it has more precise action and fewer off-target side effects compared to spironolactone. It is FDA-approved for prostate cancer but used off-label in transgender care.
  5. Flutamide — Another nonsteroidal antiandrogen, occasionally used at low doses (50 to 75 mg/day). It carries a risk of hepatotoxicity, which limits its use.
  6. Finasteride — A 5α-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). It is sometimes used as an adjunct rather than a primary antiandrogen.
  7. Medroxyprogesterone acetate (Provera, Depo-Provera) — A progestin sometimes used in place of CPA in the United States, as it has some testosterone-suppressing effects.

Why Spironolactone Dominates in the USA

The answer is primarily regulatory, not clinical:

  • CPA is not FDA-approved. Cyproterone acetate has never been approved by the U.S. Food and Drug Administration for any indication and is unavailable in the U.S. market. This is the fundamental reason spironolactone became the default antiandrogen in American transgender healthcare. As noted in the literature, spironolactone "is specifically used as an alternative to cyproterone acetate in the United States, where cyproterone acetate is not approved for medical use and is unavailable."
  • Spironolactone was already available and cheap. As a long-established generic medication on the WHO List of Essential Medicines, spironolactone was readily accessible, inexpensive, and already FDA-approved for other conditions. American physicians could prescribe it off-label without regulatory barriers.
  • Clinical concerns about CPA. Beyond regulatory unavailability, CPA has been associated with increased risk of meningioma, severe depression, and liver injury, which has led some clinicians to argue that spironolactone is a safer choice even where CPA is available.

Why Other Countries Prefer CPA or GnRH Agonists

  • CPA is approved and established. In Europe, Canada, and elsewhere, CPA has been approved for decades and has a long clinical track record. It is a more potent androgen suppressor than spironolactone, directly reducing testosterone production through its progestogenic action on the hypothalamic-pituitary-gonadal axis.
  • Spironolactone's efficacy limitations. A systematic review found that "even at high doses spironolactone treatment was not associated with a significant reduction in serum total testosterone." This is a significant clinical drawback compared to CPA and GnRH agonists, which more reliably suppress testosterone to female reference ranges. Its use in transgender women "has recently been questioned due to the various shortcomings of the medication for such purposes."
  • GnRH agonists as the gold standard. Many European guidelines, particularly in countries with nationalized healthcare systems, prefer GnRH agonists as the most effective and cleanest option, avoiding the off-target effects of both spironolactone (diuretic effects, hyperkalemia) and CPA (meningioma risk, depression). However, cost remains a barrier even in some of these systems.
  • Bicalutamide's emergence. Wikipedia notes that spironolactone's use "continues despite the rise of various accessible alternatives such as bicalutamide and cyproterone acetate with more precise action and fewer side effects." Bicalutamide is increasingly discussed in international guidelines as a well-tolerated alternative, particularly for patients who cannot tolerate or do not respond adequately to other agents.

Summary

Medication

Mechanism

Primary Regions

Key Limitation

Spironolactone

Androgen receptor blockade (weak), diuretic

USA (primary), some other countries

Weak testosterone suppression; hyperkalemia

Cyproterone acetate

Progestin + androgen receptor blockade

Europe, Canada, most non-US countries

Not FDA-approved; meningioma, depression risk

GnRH agonists

Pituitary suppression

Worldwide (where affordable)

Very high cost

Bicalutamide

Pure androgen receptor blockade

Emerging worldwide

Limited long-term data in trans care

Flutamide

Androgen receptor blockade

Occasional use

Hepatotoxicity risk

In essence, spironolactone's dominance in the United States is driven by regulatory availability rather than clinical superiority. Where CPA and GnRH agonists are accessible, they are often preferred for their more effective testosterone suppression and, in the case of GnRH agonists, cleaner side-effect profiles.

 

Sources note: This answer incorporates information from Wikipedia articles on feminizing hormone therapy and spironolactone, a ScienceDirect article on low-dose CPA treatment, a systematic review published in Clinical Endocrinology (Wiley, 2020), and a U.S. Pharmacist article (2023) on breast cancer risk in transgender women on hormonal therapy. Some clinical details are supplemented by my own knowledge where the provided context was incomplete. Several source URLs from the provided context (including Cambridge Dictionary and Merriam-Webster dictionary entries for "why," a Dota 2 Liquipedia page, and an NS International travel page) were not relevant to this topic.

Source reliability:

  • Reliable: Wikipedia (informational, cited), ScienceDirect (peer-reviewed), Wiley/Clinical Endocrinology (peer-reviewed systematic review), U.S. Pharmacist (pharmacy journal with editorial review)
  • Promotional: Drugs.com (commercial health information site with advertising)

 

Sources used by GreenPT for this answer

removed duplicate and non-contributing sources from list provided by greenpt

 

Login Form